Chronic hepatitis B in Asia-new insights from the past decade

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 131-137

  Chan, Henry Lik Yuen ^a   Jia, Jidong ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; HBeAg seroconversion; Hepatitis B; Hepatocellular carcinoma; Liver cirrhosis; Vaccination

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ASIA; AUSTRALIA; CHILD CARE; CHINA; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DRUG CHOICE; DRUG COST; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; HEPATITIS B; HEPATITIS B VIRUS; HONG KONG; HUMAN; IMMUNIZATION; INDIA; INDONESIA; INFECTION PREVENTION; INFECTION RISK; INVASIVE PROCEDURE; KOREA; LIVER BIOPSY; LIVER FIBROSIS; MALAYSIA; NEW ZEALAND; NON INVASIVE MEASUREMENT; NONHUMAN; OUTCOME ASSESSMENT; PAPUA NEW GUINEA; PHILIPPINES; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; SEROCONVERSION; SEROEPIDEMIOLOGY; SINGAPORE; TAIWAN; TREATMENT DURATION; VACCINATION; VIRUS DETECTION; VIRUS REPLICATION; VIRUS TYPING;

EID: 78650776723     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06544.x     Document Type: Review

References (83)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
2. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-73.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis c virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006; 45: 529-38.
4. Sorrell MF, Belongia EA, Costa J et al. National institutes of health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49 (Suppl.): S4-12.
5. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J. Hepatol. 2009; 51: 403-10.
6. Clements CJ, Baoping Y, Crouch A et al. Progress in the control of hepatitis B infection in the western Pacific region. Vaccine 2006; 24: 1975-82.
7. Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol. Int. 2009; 3 (Suppl. 1): 24-31.
8. Xia GL, Liu CB, Cao HL et al. Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int. Hepatol. Commun. 1996; 5: 62-73.
9. Weinbaum CM, Williams I, Mast EE et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1-20.
10. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect. Dis. 2007; 7: 402-9.
11. Snitbhan R, Scott RM, Bancroft WH, Top FH, Chiewsilp D. Subtypes of hepatitis b surface antigen in southeast asia. J. Infect. Dis. 1975; 131: 708-11.
12. Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P. Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. Southeast Asian J. Trop. Med. Public Health. 1993; 24: 239-49.
13. Caruana SR, Kelly HA, De Silva SL et al. Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the mekong region. Aust. N. Z. J. Public Health. 2005; 29: 64-8.
14. Soeung SC, Rani M, Huong V, Sarath S, Kimly C, Kohei T. Results from nationwide hepatitis B serosurvey in cambodia using simple and rapid laboratory test: implications for national immunization program. Am. J. Trop. Med. Hyg. 2009; 81: 252-7.
15. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M. Impact of the expanded program of immunization against hepatitis B infection in school children in Malaysia. Med. Microbiol. Immunol. 2005; 194: 163-8.
16. Perz JF, Elm JL Jr, Fiore AE, Huggler JI, Kuhnert WL, Effler PV. Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics 2006; 118: 1403-8.
17. Ni YH, Huang LM, Chang MH et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-93.
18. Liang XF, Bi SL, Yang WZ et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J. Infect. Dis. 2009; 200: 39-47.
19. Liang X, Bi S, Yang W et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-7.
20. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig. Dis. 1992; 10: 46-52.
21. Chan HL, Wong VW, Wong GL. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir. Ther. 2009; 14: 489-99.
22. Hadziyannis SF, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
23. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230-5.
24. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
25. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-15.
26. Chan HL, Wong ML, Hui AY et al. Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. J. Clin. Microbiol. 2003; 41: 4793-5.
27. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-62.
28. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
29. Livingston SE, Simonetti JP, Bulkow LR et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-7.
30. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133: 1458-65.
31. Sung JJ, Chan HL, Wong ML et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J. Viral Hepat. 2002; 9: 229-34.
32. Chan HL, Hui Y, Leung NW et al. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. Am. J. Gastroenterol. 2000; 95: 3547-51.
33. Chan HL, Wong GL, Tse CH et al. HBV genotype C is associated with more severe fibrosis than genotype B. Clin. Gastroenterol. Hepatol. 2009; 7: 1361-6.
34. Chan HL, Hui AY, Wong ML et al. Genotype C hepatitis B virus infection is associated with increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-8.
35. Chan HL, Tse CH, Mo F et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J. Clin. Oncol. 2008; 26: 177-82.
36. Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ. Comparison of three different sensitive assays for hepatitis B virus (HBV) DNA in monitoring response of anti-viral therapy. J. Clin. Microbiol. 2000; 38: 3205-8.
37. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-8.
38. Papatheodoridis GV, Manesis EK, Manolakopoulos S et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-9.
39. Zacharakis G, Koskinas J, Kotsiou S et al. The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective study. J. Hepatol. 2008; 49: 884-91.
40. Wong GL, Wong VW, Choi PC et al. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am. J. Gastroenterol. 2008; 103: 3071-81.
41. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
42. Iloeje UH, Yang HI, Su J et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
43. Wong VW, Chan SL, Mo F et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 2010; 28: 1660-5.
44. Chen JD, Yang HI, Iloeje UH et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-54.
45. Liaw YF, Leung NW, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
46. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
47. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
48. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
49. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 13: 1084-9.
50. Simonetti J, Bulkow L, McMahon BJ et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.
51. Yuen MF, Wong DK, Fung J et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
52. Ahn SH, Park YN, Park JY et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 2005; 42: 188-94.
53. Chan HL, Tsang SW, Leung NW et al. Occult hepatitis B virus (HBV) infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am. J. Gastroenterol. 2002; 97: 1211-15.
54. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. Hepatol. 2003; 18: 239-45.
55. EASL jury. EASL international consensus conference on hepatitis B. Consensus statement. J. Hepatol. 2003; 39: 857-61.
56. Kim WR, Flamm SL, De Bisceglie AM et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008; 47: 1363-70.
57. Kumar M, Sarin SK, Hissar S et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-84.
58. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J. Hepatol. 2007; 47: 760-7.
59. Wong GL, Wong VW, Choi PC et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2009; 7: 227-33.
60. Chan HL. Revisiting the treatment recommendation of chronic hepatitis B. Hepatology 2009; 49: 700.
61. Bedossa P, Dargère D, Paradise V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
62. Hui AY, Chan HL, Wong VW et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am. J. Gastroenterol. 2005; 100: 616-23.
63. Zeng MD, Lu LG, Mao YM et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-45.
64. Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003; 39: 222-30.
65. Wong VW, Chan HL. Transient elastography. J. Gastroenterol. Hepatol. 2010; 25: 1726-31.
66. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment. Pharmacol. Ther. 2010; 31: 1095-103.
67. Kim SU, Ahn SH, Park JY et al. Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 267-71.
68. Chan HL, Wong GLH, Choi PC et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J. Viral. Hepat. 2009; 16: 36-44.
69. Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat. 2007; 14: 360-9.
70. Wong GL, Wong VW, Choi PC et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J. Gastroenterol. Hepatol. 2009; 24: 1002-7.
71. Lim SG, Amarapurkar D, Chan HL et al. Reimbursement policies in Asia-Pacific for chronic hepatitis B. Hepatol. Int. 2010; 4: 20.
72. Chan HL. Antiviral therapy for chronic hepatitis B: the challenges of Hong Kong. J. Hepatol. 2009; 51: 1088-90.
73. Keeffe EB, Dieterich DT, Han ST et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol. Hepatol. 2006; 4: 936-62.
74. Lui YY, Tsoi KK, Wong VW et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir. Ther. 2010; 15: 145-55.
75. van Nunen AB, Hansen BE, Suh DJ et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-4.
76. Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J. Clin. Virol. 2009; 45: 114-18.
77. Fung J, Lai CL, Tanaka Y et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am. J. Gastroenterol. 2009; 104: 1940-6.
78. Lee HW, Lee HJ, Hwang JS et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51: 415-21.
79. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir. Ther. 2007; 12: 345-53.
80. Hadziyannis SJ, Sevastianos V, Rapti IN et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 (Suppl. 1): 231A.
81. Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2004; 19: 1276-82.
82. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
83. Ahn SH, Chan HL, Chen PJ et al. Chronic hepatitis B: whom to treat and for how long? Proposition, challenges, and future directions. Hepatol. Int. 2010; 4: 386-95.